首页> 外文期刊>In vivo. >Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY)
【24h】

Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY)

机译:2型糖尿病患者微量白蛋白尿缓解的相关因素:微量白蛋白尿患者早期干预的重要性(TSUGARU研究)

获取原文
           

摘要

Aim: The aim of this study was to clarify the rates of remission and progression for microalbuminuria in patients with type 2 diabetes (T2DM); and factors associated with remission and progression of diabetic nephropathy (DN). Patients and Methods: T2DM patients with a urinary albumin excretion (UAE) rate of 30-300 mg/gCr who were attending the medical clinic in the Tsugaru region in Japan were enrolled into this prospective, observational study for 36 months (N=317). We investigated the rate of remission (UAE <30 mg/g creatinine (Cr); normal albuminuria) and the rate of progression (UAE [≥]300 mg/gCr; overt proteinuria) 36 months after study registration. Results: The number of patients whose UAE levels were <30 mg/gCr (DN remission) at 36 months after registration was 64 (27.4%), and the number of patients whose UAE levels were [≥]300 mg/gCr (DN progression) at 36 months after registration was 32 (13.7%). From multiple logistic regression analysis, the sole factor that contributed to remission at 36 months after registration was the UAE levels at registration (OR: 0.99; 95% CI: 0.98-1.00, p=0.003), and the factors that contributed to progression at 36 months after registration were the levels of UAE (OR: 1.01; 95% CI: 1.01-1.02, p=0.000) and systolic blood pressure (OR: 0.96; 95% CI: 0.93-1.00, p=0.033) at registration. Conclusion: Results suggest that patients with less severe microalbuminuria among microalbuminuric patients might more commonly experience DN remission and that earlier intervention is very important for promoting microalbuminuria remission in DN.
机译:目的:本研究旨在阐明2型糖尿病(T2DM)患者微量白蛋白尿的缓解率和进展。以及与糖尿病肾病(DN)缓解和进展相关的因素。患者和方法:在日本津轻地区的医疗诊所就诊的尿白蛋白排泄(UAE)率为30-300 mg / gCr的T2DM患者参加了为期36个月的前瞻性观察性研究(N = 317) 。在研究注册后36个月,我们研究了缓解率(UAE <30 mg / g肌酐(Cr);正常蛋白尿)和进展率(UAE [≥] 300 mg / gCr;明显的蛋白尿)。结果:注册后36个月,UAE水平<30 mg / gCr(DN缓解)的患者人数为64(27.4%),而UAE水平为[≥] 300 mg / gCr(DN进展)的患者人数)在注册后36个月时为32(13.7%)。通过多重逻辑回归分析,导致注册后36个月缓解的唯一因素是注册时的阿联酋水平(OR:0.99; 95%CI:0.98-1.00,p = 0.003),以及促成病情恶化的因素。登记后36个月时登记时的阿联酋水平(OR:1.01; 95%CI:1.01-1.02,p = 0.000)和收缩压(OR:0.96; 95%CI:0.93-1.00,p = 0.033)。结论:结果表明,微白蛋白尿患者中微量白蛋白尿较轻的患者可能更常出现DN缓解,早期干预对促进DN的微白蛋白尿缓解非常重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号